Lower emissions fuel developer Quadrise (LON: QED) expects Valkor Technologies to pay $300,000 of the licence fee it owes in early November and the remaining $650,000 could be paid before the end of the year. This cash was expected in October. This is based on Valkor completing its fundraising. Shipment of the Multifuel Manufacturing unit to Utah will happen when the payments are made. The share price gained 48.3% to 2.15p.
GCM Resources (LON: GCM) has paid the £868,000 owed in deferred fees and interest to the company’s chief executive Datuk Michael Tang. He previously sent a pre-action letter of claim through Trephina Assets, his personal service company. Datuk Michael Tang had demanded immediate payment of fees and interest totalling £1.23m. The company disputes the higher figure. At the end of October, GCM had cash of £1.82m. The share price recovered 48.1% to 10p, but it remains nearly 30% lower than prior to when the letter was received.
Shares in Pacso (LON: PACS), formerly Agriterra, returned from suspension after publishing accounts for the year to March 2026. The agricultural activities in Mozambique have been sold with final regulatory approval in August when the company became a shell. The share price rose 34.9% to 0.425p.
Online wine retailer Naked Wines (LON: WINE) has launched a tender offer of up to £5.7m at 80p/share. The final decision on the size of the tender at a general meeting on 8 December when there will be a better idea of pre-Christmas trading. The full £5.7m depends on trading being at least in line with the midpoint of the 2026-27 net cash expectation range of £34m to £42m. Interim figures will be published on 11 December. An entity associated with chair Jack Pailing bought 60,000 shares at 69.78p each. The share price rebounded 19.7% to 68p.
FALLERS
Allergy treatments developer Allergy Therapeutics (LON: AGY) says challenging market conditions and lack of liquidity make it difficult to raise money and therefore it has decided to ask shareholders to agree to the biotech company leaving AIM. Costs will be reduced. Two investors own 89% of the company, which limits liquidity. Allergy Therapeutics is still considering a listing in Hong Kong. The share price slumped 68.1% to 1.275p.
Roebuck Food Group (RFG) announced late on 30 October that it wanted to raise up to €10m in the end it raised €9m at 9p/share and trading in the shares has resumed with a fall of 48.8% to 10.5p. Justin McCarthy has become group chief executive following the refocusing on greenhouse gas mitigation technology developer Glasport Bio and ruminant feed additive provider Glasport Rumen Tech, which he already runs. The number of farms using the products is expanding. Annual recurring revenues could reach €1.15m by the end of the year. Roebuck plans to take up the option to increase its GlasPort Bio stake from 37.3% to 82.3% in a share deal and it could acquire the rest of Glasport Rumen Tech. This would significantly increase the number of shares in issue. Other businesses will be sold.
Iron replacement treatment supplier Shield Therapeutics (LON: STX) reported third quarter revenues of $11.5m, which is slightly lower than in the second quarter, although US sales of ACCRUFeR were 5% ahead. The selling price is recovering with prescription volumes flat. The cost of taking full commercial control in the US means that there will be a loss this year. The share price dived 43.4% to 3.2p.
Anglesey Mining (LON: AYM) has raised £1.25m at 4.5p/share, which was a large premium to the share price. This cash will accelerate development of the Parys Mountain, including a new drilling programme. There are also plans to extend the Northern Copper Zone and Garth Daniel Zone to the northeast and east. Tavira has been appointed as joint broker. The share price declined 30.4% to 4p.